Hyperhidrosis Market Summary

Hyperhidrosis Insights and Trends

• According to DelveInsight’s analysis, hyperhidrosis market size was nearly USD 545 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• In 2025, the total number of diagnosed prevalent cases of hyperhidrosis in the 7MM was approximately 13.6 million. Among the 7MM countries, Japan accounted for the highest number of diagnosed prevalent cases.
• The hyperhidrosis treatment landscape is undergoing a shift toward non-invasive, patient-centric therapies, particularly in primary axillary hyperhidrosis. Sofpironium bromide (SOFDRA), glycopyrronium (QBREXZA), and glycopyrronium bromide (AXHIDROX) are reshaping the treatment paradigm by providing site-specific topical alternatives to injections and systemic therapies, with SOFDRA representing the most recent major innovation in the US market.
• Treatment persistence remains a key market constraint in Japan. Despite available therapies, only 0.7% of patients with primary focal hyperhidrosis were receiving ongoing medical care, while 62.3% of previously treated primary axillary hyperhidrosis patients were no longer receiving treatment, indicating substantial room to improve treatment continuity.
• The current treatment landscape remains heavily concentrated in axillary hyperhidrosis. Limited therapeutic innovation across palmar, plantar, craniofacial, and generalized disease leaves broader anatomical segments relatively underserved and creates opportunities for site-specific treatment development.
• Drug-delivery innovation is emerging as a key differentiation strategy for botulinum toxin therapy. DMT410 is designed to deliver botulinum toxin topically through the skin, potentially addressing injection-related discomfort while retaining the established therapeutic approach of botulinum toxin.
• Treatment persistence may increasingly differentiate competing therapies beyond efficacy alone. Skin irritation, anticholinergic adverse effects, short treatment duration, painful injections, and procedural burden can contribute to discontinuation, supporting demand for longer-lasting and better-tolerated treatment options.

Hyperhidrosis Market Size and Forecast

• 2025 Hyperhidrosis Market Size in the 7MM: ~USD 545 million
• 2036 Projected Hyperhidrosis Market Size in the 7MM: ~USD 1.1 billion
• Hyperhidrosis Growth Rate (2026-2036): 6.6% CAGR

DelveInsight’s “Hyperhidrosis – Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of hyperhidrosis, historical and forecasted epidemiology, as well as the hyperhidrosis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The hyperhidrosis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, hyperhidrosis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across the 7MM regions. The report highlights key unmet medical needs in hyperhidrosis and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, Spain and the United Kingdom
• Asia-Pacific: Japan

Hyperhidrosis Understanding and Treatment Algorithm

Hyperhidrosis Overview and Diagnosis

Hyperhidrosis is characterized by sweating beyond thermoregulatory requirements and is broadly classified as primary, occurring without an identifiable underlying cause, or secondary, resulting from an underlying medical condition or medication. Primary hyperhidrosis typically presents as localized, bilateral sweating, most commonly affecting the axillary, palmar, plantar, or craniofacial regions, with substantial impact on daily functioning and quality of life.

Diagnosis is primarily clinical and requires differentiation of primary from secondary hyperhidrosis. Key features supporting primary hyperhidrosis include early onset, bilateral and symmetrical localized sweating, absence of excessive sweating during sleep, chronicity, recurrent episodes, family history, and interference with daily activities. Assessment may be supplemented by gravimetry, transepidermal water loss (TEWL), and Minor’s starch-iodine test, while Hyperhidrosis Disease Severity Scale (HDSS), Hyperhidrosis Impact Questionnaire (HHIQ), and Dermatology Life Quality Index (DLQI) can be used to assess disease severity and quality-of-life impact.

Further details related to country-based variations are provided in the report…

Current Hyperhidrosis Treatment Landscape

Current treatment of hyperhidrosis includes topical antiperspirants, topical anticholinergics, oral systemic therapies, and injectable botulinum toxin. Aluminum chloride-based antiperspirants remain a commonly recommended first-line option, while newer topical anticholinergics, including glycopyrronium (QBREXZA/Rapifort Wipes), sofpironium bromide (SOFDRA/ECCLOCK Gel), and glycopyrronium bromide (AXHIDROX), provide site-specific, non-invasive treatment options for primary axillary hyperhidrosis. OnabotulinumtoxinA (BOTOX) remains an established injectable therapy, while treatment selection depends on disease severity, patient preference, and previous treatment response.

Non-pharmacological approaches, including iontophoresis, lifestyle modifications, and surgery, may also be used depending on disease presentation and treatment response. Current management may require sequential or combination therapies because available treatments differ in onset, durability, tolerability, and convenience. The treatment landscape is increasingly shifting toward convenient, non-invasive topical therapies, particularly for axillary hyperhidrosis.

Further details related to country-based variations are provided in the report…

Hyperhidrosis Unmet Needs

The section “Unmet Needs of Hyperhidrosis” outlines the critical gaps in the current diagnosis, treatment, and management of hyperhidrosis. It highlights persistent challenges related to disease recognition, treatment tolerability, access to effective therapies, and limited options across anatomical sites, while identifying areas requiring further therapeutic and clinical development.

• Underdiagnosis and delayed diagnosis
• Limited differentiation between primary and secondary hyperhidrosis
• Treatment-limiting tolerability and safety concerns
• Limited non-invasive treatment options across anatomical site

Note: Comprehensive unmet needs insights in hyperhidrosis and their strategic implications are provided in the full report.

Hyperhidrosis Epidemiology

Key Findings from Hyperhidrosis Epidemiological Analysis and Forecast

• According to DelveInsight analysis, more than 2.1 million males and 3.1 million females were affected with hyperhidrosis in the US in 2025. The higher diagnosed burden among females was attributed in the report to greater healthcare-seeking behavior and reporting of symptoms owing to their impact on quality of life and psychosocial well-being.
• Primary hyperhidrosis represented the majority of diagnosed prevalent cases across the major markets in 2025. In the US, nearly 4.8 million diagnosed cases were primary hyperhidrosis compared with approximately 0.3 million secondary cases, while in Japan, more than 5 million cases were primary and 0.4 million were secondary.
• The 18-39 years age group accounted for the largest diagnosed prevalent hyperhidrosis population in the US and Japan in 2025, with more than 2.8 million and nearly 3 million cases, respectively. This distribution is consistent with the observation that primary hyperhidrosis typically begins during adolescence or early adulthood.
• Axillary hyperhidrosis represented the largest site-specific diagnosed prevalent population in 2025. In Japan, more than 3.5 million cases were attributed to axillary hyperhidrosis, followed by approximately 2.3 million craniofacial, 2.2 million palmar, and 2.1 million plantar cases.

Hyperhidrosis Drug Analysis & Competitive Landscape

The hyperhidrosis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the hyperhidrosis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the hyperhidrosis therapeutics market.

Approved Therapies Hyperhidrosis

Glycopyrronium (QBREXZA/RAPIFORT Wipes 2.5%): Journey Medical Pharma / Maruho

QBREXZA/RAPIFORT Wipes 2.5% is a topical anticholinergic indicated for the treatment of primary axillary hyperhidrosis in adult and pediatric patients aged 9 years and older. It is a once-daily, self-administered wipe formulation that reduces excessive sweating through localized inhibition of sweat gland stimulation.

• In January 2022, Maruho received Japan’s Ministry of Health, Labor and Welfare (MHLW) approval for glycopyrronium tosylate hydrate (RAPIFORT Wipes 2.5%) for primary AHH in Japan, triggering a USD 2.5 million-milestone payment to Journey Medical Corporation.
• In June 2018, the US FDA approved QBREXZA for primary AHH for excessive underarm sweating for pediatric and adult patients.

Hyperhidrosis Pipeline Analysis

ET-01: Eirion Therapeutics

ET-01 is an investigational topical botulinum formulation being developed by Eirion Therapeutics for the treatment of primary axillary hyperhidrosis. It utilizes a proprietary nanoemulsion-based transdermal delivery technology designed to enable penetration of botulinum toxin through the skin, potentially avoiding the pain, bleeding, and bruising associated with injectable botulinum toxin products.

ET-01 is currently in Phase II development for primary axillary hyperhidrosis. The therapy acts by inhibiting acetylcholine release from cholinergic nerve endings, thereby reducing eccrine sweat gland activity.

DMT410: Dermata Therapeutics/ Revance Therapeutics

DMT410 is an investigational, needle-free topical botulinum toxin delivery platform being developed by Dermata Therapeutics in collaboration with Revance Therapeutics for the treatment of primary axillary hyperhidrosis (AHH). The therapy combines Dermata's proprietary XYNGARI technology with Revance's botulinum toxin product, DAXXIFY, enabling the topical delivery of botulinum toxin across the skin.

DMT410 is intended to offer a non-invasive alternative to injectable botulinum toxin therapies, potentially minimizing the pain, bruising, and discomfort commonly associated with injections. Early clinical studies have demonstrated encouraging efficacy and a favorable safety profile, supporting the continued clinical development of DMT410 as a potential treatment option for patients with primary axillary hyperhidrosis.

• In January 2025, Dermata Therapeutics entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to evaluate DMT410 in combination with DAXXIFY for the treatment of primary axillary hyperhidrosis (AHH). Following the agreement, the companies have continued to advance the program by finalizing the study design and completing start-up activities for the planned Phase IIa clinical trial. The study is intended to assess the safety and efficacy of the XYNGARI platform in combination with DAXXIFY as a topical, needle-free treatment option for patients with primary AHH.

Hyperhidrosis Key Players, Market Leaders and Emerging Companies

• Eirion Therapeutics
• Dermata Therapeutics/ Revance Therapeutics
• Atacama Therapeutics
• Journey Medical Corporation/ Maruho
• Dr. Wolff Group/ Axunio Pharma GmbH
• Botanix Pharmaceuticals/ Kaken pharmaceutical
• AbbVie/ Allergan
• Hisamitsu Pharmaceutical
• And more

Hyperhidrosis Drug Updates

• In July 2025, Dermata Therapeutics announced the grant of a second Australian patent for DMT410, a topical botulinum toxin delivery approach for hyperhidrosis. The company had completed Phase I proof-of-concept studies and planned to initiate a Phase IIa study evaluating XYNGARI with DAXXIFY in primary axillary hyperhidrosis.
• In February 2024, Eirion Therapeutics announced that it would present an update on its topical and liquid injectable botulinum programs, including its topical botulinum candidate ET-01, at the 2024 IMCAS World Congress in Paris.

Hyperhidrosis Market Outlook

The hyperhidrosis market is evolving toward convenience-adjusted treatment value, with efficacy increasingly considered alongside formulation, dosing frequency, treatment burden, and long-term usability. Commercial opportunity is likely to extend beyond current prescription users as greater recognition of hyperhidrosis converts patients currently relying on self-management or delaying care into treated populations. At the same time, the concentration of innovation in primary axillary disease leaves site-specific treatment gaps in palmar, plantar, and craniofacial hyperhidrosis, creating opportunities for differentiated therapies and delivery approaches.

• In 2025, the US hyperhidrosis market was estimated to be more than ~USD 280 million, and is expected to grow during the forecast period (2026–2036), supported by increasing disease awareness, diagnosis, and adoption of newer topical therapies.
• The total market size of EU4 and the UK was estimated to be nearly USD 90 million in 2025.
• Among EU4 and the UK, Germany accounted for the highest market share, with more than USD 20 million in 2025, while Spain represented the lowest market share with nearly USD 15 million.
• In 2025, the total hyperhidrosis market size in Japan was more than USD 175 million, and is anticipated to increase during the forecast period (2026–2036).

Drug Class/Insights into Leading Emerging Therapies in Hyperhidrosis (2022–2036 Forecast)

Biologic: Biologic therapy in hyperhidrosis is primarily represented by botulinum toxin, a neurotoxin that inhibits acetylcholine release from cholinergic nerve terminals supplying eccrine sweat glands, thereby reducing localized sweating. Botulinum toxin is used as a minimally invasive treatment for focal hyperhidrosis, particularly when conservative therapies are inadequate.

Hyperhidrosis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the hyperhidrosis drug uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Drug uptake is expected to be influenced by treatment positioning, duration of symptom control, and repeat-treatment requirements. Therapies offering sustained control with lower treatment burden may support greater persistence and recurring treatment demand.

Detailed insights of emerging therapies' drug uptake is included in the report…

Market Access and Reimbursement of therapies in Hyperhidrosis

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

EU4 and the UK

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report.

Hyperhidrosis Therapies Price Scenario & Trends

Pricing and analogue assessment of hyperhidrosis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Pricing of Hyperhidrosis Approved Drugs

The annual cost of treatment with onabotulinumtoxinA (BOTOX) in the US in 2025 is estimated at approximately USD 1,000, based on the recommended dosing and retreatment frequency.

Industry Experts and Physician Views for Hyperhidrosis

To keep up with hyperhidrosis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the hyperhidrosis emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in hyperhidrosis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights at country level. Centers such as the St John's Institute of Dermatology, St George’s Hospital, Hôpital Saint-Louis, and Aichi Medical University School of Medicine etc. etc. were contacted.

Their opinion helps understand and validate current and emerging hyperhidrosis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in hyperhidrosis.

Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and market intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.

In the SWOT analysis of hyperhidrosis, strengths, weaknesses, opportunities, and threats are assessed in terms of disease awareness and diagnosis, treatment options, patient burden, competitive landscape, treatment accessibility, and limitations of existing therapies. The analysis considers the shift toward prescription topical anticholinergics, the chronic nature of hyperhidrosis and recurring treatment demand, gaps between disease prevalence, diagnosis, and treatment, opportunities across different hyperhidrosis sites, reimbursement barriers, and competition from established treatment options.

The attribute analysis evaluates therapies based on relevant treatment attributes, including efficacy, safety, tolerability, route of administration, convenience, and clinical development stage. The analysis considers available efficacy and safety data while accounting for differences in development stage and efficacy endpoints. In addition, treatment convenience, localized delivery, adherence, and the potential to reduce reliance on invasive procedures are considered when assessing the positioning of emerging therapies.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of hyperhidrosis, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the hyperhidrosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM hyperhidrosis market.

Report Insights

• Hyperhidrosis Patient Population Forecast
• Hyperhidrosis Therapeutics Market Size
• Hyperhidrosis Pipeline Analysis
• Hyperhidrosis Market Size and Trends
• Hyperhidrosis Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Hyperhidrosis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Hyperhidrosis Treatment Addressable Market (TAM)
• Hyperhidrosis Competitive Landscape
• Hyperhidrosis Major Companies Insights
• Hyperhidrosis Price Trends and Analogue Assessment
• Hyperhidrosis Therapies Drug Adoption/Uptake
• Hyperhidrosis Therapies Peak Patient Share analysis

Report Assessment

• Hyperhidrosis Current Treatment Practices
• Hyperhidrosis Unmet Needs
• Hyperhidrosis Clinical Development Analysis
• Hyperhidrosis Emerging Drugs Product Profiles
• Hyperhidrosis Market Attractiveness
• Hyperhidrosis Qualitative Analysis (SWOT and Attribute analysis)

FAQs

Market Insights

• What was the hyperhidrosis market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of hyperhidrosis?
• What are the disease risks, burdens, and unmet needs of hyperhidrosis? What will be the growth opportunities across the 7MM concerning the patient population with hyperhidrosis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of hyperhidrosis? What are the current guidelines for treating hyperhidrosis in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the hyperhidrosis market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.